Scholarlink

Purpose <p>This study aims to develop a physiologically based pharmacokinetic (PBPK) absorption model incorporating gastrointestinal (GI) fluid dynamics and to quantitatively evaluate the effects of GI fluid dynamics on the oral absorption of various drugs in humans.</p> Methods <p>By incorporating our previously developed physiologically based fluid kinetic (PBFK) model describing GI fluid dynamics into a PBPK absorption model, we constructed the Integrated Liquid and Intestinal Absorption Drug (ILIAD) model, which dynamically describes drug concentrations based on the GI disposition of both fluid and drugs. The scaling factors (SF) for membrane permeability, CYP3A-catalyzed metabolism, and P-gp-mediated efflux introduced into the ILIAD model were obtained as common parameters for all drugs through simultaneous optimization using the reported plasma concentration–time profiles of atenolol, midazolam, and talinolol.</p> Results <p>Simulation analysis using the ILIAD model accurately predicted the bioavailability and plasma concentration–time profile of various CYP3A and/or P-gp substrate drugs. Sensitivity analysis demonstrated that changes in GI fluid dynamics can lead to variations in GI fluid volume, resulting in altered drug absorption, particularly for low-permeability drugs. However, further analyses demonstrated that even high-permeability drugs may be affected by the GI fluid dynamics when they are substrates of CYP3A or P-gp.</p> Conclusion <p>Our ILIAD model is expected to be a useful tool for predicting oral drug absorption properties, including the effects of changes in GI fluid dynamics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantitative Analysis of the Effect of Gastrointestinal Water Dynamics on Oral Drug Absorption using a Physiologically Based Integrated Liquid and Intestinal Absorption Drug (ILIAD) Pharmacokinetic Model

  • 期刊论文

  • 发表日期：

    2026年2月25日

查看全文
  • Satoru Suzuki,
  • Ikumi Tamai,
  • Yoshiyuki Shirasaka

摘要

Purpose

This study aims to develop a physiologically based pharmacokinetic (PBPK) absorption model incorporating gastrointestinal (GI) fluid dynamics and to quantitatively evaluate the effects of GI fluid dynamics on the oral absorption of various drugs in humans.

Methods

By incorporating our previously developed physiologically based fluid kinetic (PBFK) model describing GI fluid dynamics into a PBPK absorption model, we constructed the Integrated Liquid and Intestinal Absorption Drug (ILIAD) model, which dynamically describes drug concentrations based on the GI disposition of both fluid and drugs. The scaling factors (SF) for membrane permeability, CYP3A-catalyzed metabolism, and P-gp-mediated efflux introduced into the ILIAD model were obtained as common parameters for all drugs through simultaneous optimization using the reported plasma concentration–time profiles of atenolol, midazolam, and talinolol.

Results

Simulation analysis using the ILIAD model accurately predicted the bioavailability and plasma concentration–time profile of various CYP3A and/or P-gp substrate drugs. Sensitivity analysis demonstrated that changes in GI fluid dynamics can lead to variations in GI fluid volume, resulting in altered drug absorption, particularly for low-permeability drugs. However, further analyses demonstrated that even high-permeability drugs may be affected by the GI fluid dynamics when they are substrates of CYP3A or P-gp.

Conclusion

Our ILIAD model is expected to be a useful tool for predicting oral drug absorption properties, including the effects of changes in GI fluid dynamics.